Absolute and relative lower extremity peripheral arterial disease DALYs rate attributable to 2^nd level risk factors in Chile. by Camilo Briones-Valdivieso (21567535)

Subjects:

Tested levels of fertilization, microbiological preparations and forecrop under optimal water conditions. by Dominika Radzikowska-Kujawska (14439076)

Water footprint at regional levels in China. by Jianqin Ma (20328414)

Subjects:

Prediction for the ecological functional composition of the bacterial community from Functional Annotation of Procaryotic Taxa (FAPROTAX) (A) and relationship between fertilization... by Qian Wang (32718)

Prevalence of osteoporosis classified by sex, and urinary cadmium level compare between 2019 and 2022. by Aroon La-up (14095691)

Subjects:

Expression level (2^-ΔCq) of microRNA in the cerebellum of control, pinealectomized (PINX) and melatonin-treated (PINX-MEL) rats. by Mísia Helena da Silva Ferro (20623666)

Expression level (2^-ΔCq) of microRNA in the sperm of control, pinealectomized (PINX) and melatonin-treated (PINX-MEL) rats. by Mísia Helena da Silva Ferro (20623666)

Expression level (2^-ΔCq) of microRNA in the hypothalamus of control, pinealectomized (PINX) and melatonin-treated (PINX-MEL) rats. by Mísia Helena da Silva Ferro (20623666)

Baseline and Post-Treatment Serum Levels of NT-proBNP in Each Investigational Group. by Káryta Suely Macêdo Martins (22404155)

Subjects:

Relative expression levels in TNF-α, IL-6, and p53 in co-culture and CM treatment of hypoxic and normoxic PANC-1 cells with CD8+ T-cells. by Eiman Abdo (20642254)

Subjects:

Maximum likelihood estimates of trans-log mean stochastic function. by James Anaba Akolgo (14129379)

Map with color coding showing the relative risk of loss at the regional level for each country in Sub-Saharan Africa. by Beatrice T. Nganso (4114768)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects: